Prevalence of selected risk factors and comorbidities at baseline and 3 years
| Comorbidity | Prevalence at baseline (month 0 for group I and month 6 for group II), N (%) | Prevalence at follow-up after 3 years, N (%) | Incidence for 100 patient-years (95% CI) (absolute incidence as %) |
| Risk factors | |||
| CV risk | |||
| Diabetes | 39 (5.1) | 51 (6.6) | 0.6 (0.3 to 1.0) (1.6) |
| High blood pressure | 238 (30.9) | 270 (35.1) | 2.1 (1.5 to 2.9) (4.2) |
| Hyperlipidaemia | 149 (19.4) | 170 (22.1) | 1.1 (0.7 to 1.7) (2.7) |
| Obesity (BMI≥30 kg/m2) | 114 (14.8) | 124 (16.1) | 1.5 (1.0 to 2.1) (1.3) |
| Smoking | 122 (15.9) | 104 (13.5) | 0.5 (0.2 to 0.9) (−2.3) |
| Comorbidities | |||
| MACE | |||
| Myocardial infarct | 13 (1.7) | 18 (2.3) | 0.2 (0.1 to 0.5) (0.6) |
| Angina | 9 (1.2) | 17 (2.2) | 0.4 (0.2 to 0.7) (1.0) |
| Stroke | 16 (2.1) | 29 (3.8) | 0.6 (0.3 to 1.0) (1.7) |
| Obliterating arteriopathy | 8 (1.0) | 15 (2.0) | 0.3 (0.2 to 0.7) (0.9) |
| Cancer | |||
| Colon | 2 (0.3) | 2 (0.3) | 0 (0) (0) |
| Breast | 23 (3.0) | 27 (3.5) | 0.2 (0.1 to 0.5) (0.5) |
| Lung | 1 (0.1) | 2 (0.3) | 0.0 (0.0 to 0.3) (0.2) |
| Prostate | 3 (0.4) | 4 (0.5) | 0.0 (0.0 to 0.3) (0.1) |
| Uterus | 7 (0.9) | 7 (0.9) | 0 (0) (0) |
| Skin (all types) | 26 (3.4) | 36 (4.7) | 0.5 (0.2 to 0.8) (1.3) |
| Lymphoma | 2 (0.3) | 3 (0.4) | 0.0 (0.0 to 0.3) (0.1) |
| Osteoporosis | |||
| Bone fracture | 245 (31.9) | 292 (38.2) | 3.1 (2.4 to 4.2) (6.1) |
BMI, body mass index; CV, cardiovascular; MACE, major CV event.